Valeant Announces CFO Succession Plan And Additional Executive Appointment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech stocks weigh on Wall Street as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- U.S. EV market shows signs of bottoming out: Bernstein
Valeant Pharmaceuticals (VRX) PT Lifted to $250 at Guggenheim Post Q1
April 29, 2015 10:16 AM EDTGuggenheim analyst Louise Chen reiterated a Buy rating and boosted her price target on Valeant Pharmaceuticals (NYSE: VRX) to $250.00 (from $210.00) following Q1 beat and better-than-expected 2016 outlook.
Chen commented, "The 1Q15 beat and better-than-expected outlook for '16+ support our positive thesis for... More
Valeant Pharma (VRX) Reports Q1 EPS of $2.36; Announces CFO Transition
April 29, 2015 6:16 AM EDTValeant Pharma (NYSE: VRX) reported Q1 EPS of $2.36, versus $1.76 reported last year. Revenue for the quarter came in at $2.2 billion, versus $1.89 billion reported last year.
Valeant also announced that Howard B. Schiller has advised the Company of his decision to step down as Chief Financial Officer once a successor is appointed. In order to facilitate a smooth transition, Mr. Schiller will remain in his current position as the search for his replacement proceeds. With the support of Valeant's Board of Directors, Mr. Schiller will remain on the Valeant Board and, with the Board's continued... More
